UK MHRA Indefinite CE Marking Recognition: A New Era for Great Britain Market Access
Medical Device Global Market AccessSummary
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) announces a significant policy change that will indefinitely recognize CE-marked medical devices, easing the transition from the EU's CE marking system to the UK's UKCA mark. This decision removes the previously set deadline of mid-2030 for devices to obtain UKCA certification, providing clarity and stability for manufacturers who have invested in compliance with the EU's Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR).
The new policy applies specifically to devices compliant with the EU regulations, while manufacturers must still appoint a UK Responsible Person (UKRP) to manage registrations and post-market obligations. The recognition of CE marking does not affect Northern Ireland, which continues to follow EU rules. While the UKCA marking pathway remains available for those not pursuing CE marking, it is no longer mandatory for all devices.
Industry experts recommend that manufacturers reassess their UK market strategies in light of this announcement, confirm agreements with UKRPs, and stay updated on the legislative process to formalize this policy change. Maintaining thorough documentation for EU compliance is also emphasized as essential for accessing the Great Britain market.
Show Notes
The UK MHRA has announced a major policy shift: it will indefinitely recognize CE-marked medical devices that comply with the EU's MDR and IVDR. This episode breaks down the October 21, 2026 announcement, explaining what the removal of the 2030 UKCA deadline means for manufacturers. We cover the continued, critical role of the UK Responsible Person (UKRP), the status of the UKCA mark as a parallel pathway, and the pending legislation needed to formalize this change. Tune in for practical steps your regulatory team should take now to leverage this simplified route to the Great Britain market.
Key Questions: - What does the MHRA's indefinite recognition of CE marking mean for my device? - Is the 2030 deadline for UKCA marking officially gone? - Do I still need a UK Responsible Person (UKRP) to sell in Great Britain? - How does this policy affect devices certified under the EU MDR versus the old directives? - What is the status of the UKCA mark now? - When will this policy announcement officially become law? - What practical steps should my regulatory team take right now? - Does this change apply to Northern Ireland?
Sources: - https://www.gov.uk/government/news/uk-government-announces-indefinite-recognition-of-ce-marking-for-medical-devices - https://citeline.informa.com/regulatory/uk-recommends-indefinite-ce-marking-for-devices-in-great-britain - https://www.digitalhealth.net/2026/10/ce-marked-medical-devices-granted-indefinite-recognition/ - https://www.hilldickinson.com/insights/articles/medical-devices-update-uk-confirms-indefinite-recognition-ce-marking
How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including providing UK Responsible Person (UKRP) services to ensure your compliance in Great Britain. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers, helping you get to market faster. Whether you're a startup or a multinational, we provide the strategic support you need for expansion. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
More from Medical Device Global Market Access
South Korea's Ministry of Food and Drug Safety (MFDS) has renewed its commitment to the 'Medical Product Approval and Review Innovation Plan,' aiming to approve innovative medical devices within 240 days. This episode details the plan's three core components—a new detailed approval checklist, formal pre-submission meetings, and a parallel, rolling review system—and explores what these changes mean for manufacturers seeking faster market entry into South Korea.
China's NMPA has released its final Good Manufacturing Practice (GMP) inspection guideline, which becomes mandatory on November 1, 2026. This episode provides a detailed breakdown of the 200 inspection items, with a special focus on the 39 high-risk critical points that can lead to an automatic inspection failure. We outline a clear, actionable strategy for medical device manufacturers, both domestic and foreign, to conduct gap analyses, update their quality systems, and prepare for the stringent new requirements to maintain market access in China.
China's National Medical Products Administration (NMPA) is enforcing a revised Good Manufacturing Practice (GMP) for medical devices starting November 1, 2026. This episode provides a practical guide for quality and regulatory teams on how to prepare for this first major update since 2014. We cover the stricter requirements for lifecycle risk management, supplier controls, and contract manufacturing (entrusted production), and outline the concrete steps manufacturers must take to ensure their quality management systems are compliant by the deadline to avoid enforcement actions.
Indonesia is implementing mandatory Halal certification for Class A medical devices, with a critical deadline of October 18, 2026. This episode breaks down what the Halal Product Assurance Law means for manufacturers of low-risk devices. We cover the scope of affected products, the intricacies of the certification process overseen by the BPJPH, and the comprehensive requirements that extend from raw materials to final distribution. We provide practical, actionable steps for regulatory, quality, and market-access teams to prepare for this significant compliance shift and maintain access to the Indonesian market.
Swissmedic has activated the importer linking function in the swissdamed database as of October 1, 2026. This creates a new mandatory step for Swiss importers, who now have until April 1, 2027, to electronically link their actor registration (CHRN) to the devices they place on the market. This episode breaks down the new obligation, explains its dependency on prior device registration by manufacturers and Swiss Authorized Representatives (CH-REPs), and outlines practical steps for all economic operators to ensure compliance before the deadline.